MedPath

International Aids Vaccine Initiative

πŸ‡°πŸ‡ͺKenya
Ownership
-
Established
1996-01-01
Employees
-
Market Cap
-
Website
http://www.iavi.org

A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

Phase 1
Conditions
HIV Infections
First Posted Date
2013-09-09
Last Posted Date
2018-01-11
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
21
Registration Number
NCT01937455
Locations
πŸ‡¬πŸ‡§

Surrey Clinical Research Centre, Guildford, United Kingdom

πŸ‡¬πŸ‡§

Southampton Centre for Biomedical Research, Southampton, United Kingdom

Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2012-10-15
Last Posted Date
2015-08-26
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
65
Registration Number
NCT01705990
Locations
πŸ‡°πŸ‡ͺ

Kenya AIDS Vaccine Initiative, Nairobi, Kenya

πŸ‡·πŸ‡Ό

Project San Francisco, Kigali, Rwanda

πŸ‡¬πŸ‡§

St. Stephen's Centre, London, United Kingdom

Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2011-12-22
Last Posted Date
2013-09-02
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
75
Registration Number
NCT01496989
Locations
πŸ‡°πŸ‡ͺ

Kenya AIDS Vaccine Initiative, Kangemi, Nairobi, Kenya

πŸ‡·πŸ‡Ό

Projet San Francisco, Kigali, Rwanda

πŸ‡ΊπŸ‡¬

Uganda Virus Research Institute-IAVI, Entebbe, Uganda

A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2011-06-10
Last Posted Date
2011-06-10
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
115
Registration Number
NCT01371175
Locations
πŸ‡°πŸ‡ͺ

KAVI (Kenya AIDS Vaccine Initiative), Nairobi, Kenya

πŸ‡¬πŸ‡§

Guys and St. Thomas' Hospital, London, United Kingdom

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2010-12-21
Last Posted Date
2013-02-11
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
147
Registration Number
NCT01264445
Locations
πŸ‡°πŸ‡ͺ

Kenya AIDS Vaccine Initiative, Nairobi, Kenya

πŸ‡ΊπŸ‡¬

Uganda Virus Research Institute-IAVI, Entebbe, Uganda

πŸ‡ΊπŸ‡¬

Medical Research Council, Masaka, Uganda

and more 1 locations

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2010-10-06
Last Posted Date
2012-12-17
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
218
Registration Number
NCT01215149
Locations
πŸ‡ΊπŸ‡Έ

Brigham and Women's Hospital, Boston, Massachusetts, United States

πŸ‡°πŸ‡ͺ

Kenya AIDS Vaccine Initiative, Kangemi, Kenya

πŸ‡·πŸ‡Ό

Projet San Francisco, Kigali, Rwanda

and more 3 locations

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: FTC/TDF
Drug: Placebo
First Posted Date
2009-09-03
Last Posted Date
2010-08-09
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
72
Registration Number
NCT00971230
Locations
πŸ‡°πŸ‡ͺ

Kenya Medical Research Institute, Center for Geographic Medicine Research - Coast, Kilifi, Kenya

πŸ‡°πŸ‡ͺ

Kenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

Phase 1
Completed
Conditions
HIV Infection
Interventions
Drug: FTC/TDF
Drug: Placebo
First Posted Date
2009-07-02
Last Posted Date
2011-08-25
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
72
Registration Number
NCT00931346
Locations
πŸ‡ΊπŸ‡¬

MRC-Entebbe, Entebbe, Uganda

Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine

Phase 1
Completed
Conditions
HIV Infections
First Posted Date
2009-05-15
Last Posted Date
2013-02-11
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
32
Registration Number
NCT00902824
Locations
πŸ‡¬πŸ‡§

St Stephen's Centre Chelsea and Westminster Hospital, London, United Kingdom

Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid

Phase 2
Completed
Conditions
Human Immunodeficiency Virus Infections
HIV Infections
First Posted Date
2009-04-27
Last Posted Date
2012-12-17
Lead Sponsor
International AIDS Vaccine Initiative
Target Recruit Count
91
Registration Number
NCT00888446
Locations
πŸ‡ΏπŸ‡¦

Desmond Tutu HIV Centre Cape Town, Cape Town, South Africa

πŸ‡ΏπŸ‡¦

Medunsa, South Africa, South Africa

πŸ‡ΏπŸ‡¦

Perinatal HIV Research Unit, Baragwanath Hospital, Soweto, South Africa

and more 2 locations
Β© Copyright 2025. All Rights Reserved by MedPath